Feb 7, 2014
Market Report: Shire suffers as drug fails trials
Highly paid pharmaceutical analysts may have been totally relaxed after Shire said overnight that Vyvanse, its treatment for major depressive disorder , had failed two late-stage clinical trials, but private shareholders couldn't have been too happy to see the shares retreat 30p at one stage before closing 19p cheaper at 3122p.
$4.2 billion deal gives ViroPharma execs huge paydays
Former ViroPharma President and CEO Vincent Milano held stock and options valued at nearly $50 million when the company was sold to Shire Shire's $4.2 billion acquisition of ViroPharma last month generated a huge payday for ViroPharma's top executives and board members.
SHIRE -ViroPharma announces tender offer for its 2.00% Convertible Senior Notes Due 2017
Earlier in the day on January 24, 2014 , Shire completed the tender offer for all of the outstanding shares of common stock of ViroPharma , consummated the merger of ViroPharma into Venus Newco, Inc. , a wholly owned subsidiary of Shire, and terminated trading of ViroPharma's common stock on NASDAQ, and the directors of ViroPharma immediately prior ... (more)
Shire's offer for ViroPharma stock? $50 per share
The tender offer included as part of Shire's $4.2 billion acquisition of ViroPharma, an Exton, Pa., specialty biopharmaceutical company, expired at midnight on Jan. 23. As of that time, about 53.7 million shares, or 79.5 percent of the Viropharma's outstanding shares, had been validly tendered.
Shire waives condition for ViroPharma acquisition
Shire said Wednesday it has waived the Office of Fair Trading approval condition that was part of its previously announced $50 per share tender offer for all of the outstanding shares of ViroPharma Inc. The London-based Office of Fair Trading [OFT] is a government department in the United Kingdom that reviews merger proposals and enforces consumer ... (more)